Sobi Will Present Gamifant Data in Rotterdam
Healthcare providers and researchers will review new clinical findings on this monoclonal antibody treatment.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to prioritize patient outcomes when presenting new clinical research data?
Sobi is scheduled to present clinical data on its anti-interferon gamma monoclonal antibody, Gamifant, at the Histiocyte Society 2026 meeting in Rotterdam. The presentation, set for September 26-29, 2026, highlights pooled analysis of patient survival outcomes.
Why it matters
Operators in the specialty pharmaceutical and clinical research sectors track these data releases to evaluate shifts in treatment efficacy for primary haemophagocytic lymphohistiocytosis. Such clinical milestones influence the adoption trajectory and clinical utility of specialized rare disease therapies.
Sobi, which reported 2025 revenue of SEK 28 billion, will feature Gamifant research selected as one of the 10 highest-scoring posters at the meeting. The therapy is currently approved for adult and pediatric primary HLH and is administered via a one-hour infusion.
The players
Sobi
A Swedish specialty pharmaceutical company focused on rare diseases with approximately 2,000 employees.
Histiocyte Society
An international professional organization that facilitates clinical research and scientific exchange on histiocytic disorders.
The details
Gamifant functions as an anti-interferon gamma monoclonal antibody designed to neutralize the cytokine to halt hyperinflammation. The upcoming presentation includes a pooled analysis comparing pre- and post-transplant survival outcomes for patients with primary haemophagocytic lymphohistiocytosis. By integrating these outcomes, researchers can better assess the long-term clinical role of the one-hour infusion therapy in complex transplant pathways.
Timeline
The Histiocyte Society 2026 meeting occurs September 26-29, 2026.
Sobi reported annual revenue of SEK 28 billion for 2025.
Market Landscape
This presentation follows the competitive pattern of high-scoring poster selections seen in the Robert J. Arceci Prize evaluation process. It marks an effort by Sobi to reinforce the clinical profile of its primary HLH therapy against established standards of care.
Operators and clinical partners should monitor the final pooled survival findings as a signal for potential changes in treatment protocols for HLH patients. Review the long-term post-transplant data to determine if the therapeutic impact shifts current procurement or patient-management requirements.
The takeaway
The data presentation underscores the importance of longitudinal survival outcomes in gaining clinical consensus for specialized antibody treatments. Operators should monitor the Histiocyte Society findings for potential impacts on long-term clinical adoption of rare disease therapies.
Further reading
For broader trends in specialized rare disease therapeutics, visit the Healthcare section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust pharmaceutical companies to prioritize patient outcomes when presenting new clinical research data?
